Anifrolumab demonstrated superiority across multiple efficacy endpoints in patients with systemic lupus erythematosus in Phase III TULIP 2 trial
12 November 2019 07:00 GMT Anifrolumab demonstrated superiority across multiple efficacy endpointsin patients with systemic lupus erythematosus in Phase III TULIP 2 trial Anifrolumab achieved a statistically significant reductionin disease activity, a statistically significant reduction in oralorticosteroid use and improvement in skin manifestations AstraZeneca today presented detailed results from the positive Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of moderate to severe systemic lupus erythematosus (SLE), which